Diclofenac Induced Paroxysmal Atrial Fibrillation

Öz

Introduction: Diclofenac sodium is commonly used medication for pain relief and reducing inflammation. Adverse effects of diclofenac are well defined in the literature but none of the patients described previously in the literature presented with diclofenac induced paroxysmal atrial fibrillation (PAF) as in our case. Case Report: A 48 year old male admitted to emergency department with severe headache. The patient had history of migraine. Physical examination of the patient revealed no pathologic sign and 75 mg diclofenac sodium administered intramuscularly for headache. He had severe attack of palpitation and dispne 20-30 minutes after administrating diclofenac sodium. Electrocardiography was consistent with atrial fibrillation (AF) with the ventricular rate of 140 beats/min. The patient’s heart rate was controlled. The patient’s rhythm returned to sinus rhythm spontaneously after 12 hours. Conclusion: The most common sustained arrhythmia is AF. The estimated prevalence of AF is 0.4% to 1% in the general population. Studies showed that 40.2% of patients with AF was PAF. Underlying cause of PAF is similar to causes of sustained AF. Any report about PAF due to diclofenac was not reported before in the literature. It should be taken into account that diclofenac may cause PAF

Anahtar Kelimeler

• Diclofenac, adverse effects, paroxysmal atrial fibrillation

Kaynakça

1. Ciccolunghi SN, Chaudri HA, Schubiger BI. The value and results of long-term studies with diclofenac sodium (Voltarol). Rheumatol Re- habi. 1979; Suppl 2: 100-15.
2. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal antiinflammatory drugs increase the risk of atherothrombosis? Meta- analysis of randomised trials. BMJ 2006; 332: 1302-8. [CrossRef]
3. Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflam- matory drugs after acute myocardial infarction. Circulation 2006; 113: 2906-13. [CrossRef]
4. Takahashi N, Seki A, Imataka K, Fujii J. Clinical features of paroxysmal atrial fibrillation. An observation of 94 patients. Jpn Heart J 1981; 22: 143-9. [CrossRef]
5. Schmidt M, Christiansen CF, Mehnert F, Rothman KJ, Sorensen HT. Non- steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ 2011; 343: d3450. [CrossRef]
6. Bettoni M, Zimmermann M. Autonomic tone variations before the onset of paroxysmal atrial fibrillation. Circulation 2002; 105: 2753-9. [CrossRef]
7. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 2007; 50: 2021-8. [CrossRef]